The growth and metastasis suppressing activity of FXR agonist Px20606 (10 mg/kg/d) in this orthotopic xenograft model with either SK-Hep-1 or SK-GI-18 is only slightly less efficacious compared to Sorafenib (NexavarTM), presently the only medicament approved for treatment of advanced HCC [48], which was administered at a much higher dose, however (100 mg/kg/d or 50 mg/kg/d). The gene discussed is NR1H4; the disease is hepatocellular carcinoma.